Raising funds to develop diagnostic support AI through a third-party allotment of shares
First written in FY2021-Q2. 1 of 2 entries say "Achieved", first in FY2021-Q3. Latest entry: FY2021-Q3.
No other company in this theme has enough history to compare yet.
- FY2021-Q3AchievedAnnual report
「16 November 2020, Board of Directors resolution; 2 December 2020, payment date. During the cumulative period of the first 9 months of the current consolidated fiscal year, share capital increased by ¥399.966 million and capital surplus increased by ¥399.966 million.」
For the third-party allotment with Focus Systems and Gakken Holdings as the allottees, payment was completed on 2 December 2020 and the funds for developing diagnostic-support AI were raised. - FY2021-Q2First statedAnnual report
「③ Issue price: ¥766 per share ④ Total issue amount: ¥799.933 million ⑦ Issue schedule: 16 November 2020, Board of Directors resolution; 2 December 2020, payment date ⑩ Use of funds: We are developing diagnostic-support AI systems for psychiatric and other fields, with the aim of obtaining approval as the world's first language-based AI medical device. The funds will be allocated to these developments during the planned spending period from December 2020 to March 2023.」
The company resolved to conduct a third-party allotment with Focus Systems and Gakken Holdings as the allottees and newly disclosed plans to raise ¥799.933 million. The funds will be allocated from December 2020 to March 2023 to develop diagnostic-support AI systems for psychiatric and other fields, with the aim of obtaining approval as the world's first language-based AI medical device.